Figure S1: Funnel plot for publication bias in RCTs assessing the effect of pregabalin in neuropathic pain. The broken line represents the mean difference for all trials.




Figure S2: Effect of pregabalin on the risk of weight gain in patients with neuropathic pain

	Pregab	alin	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
2.1.1 Central neurop	athic pain						
Kim 2011	6	110	2	109	8.6%	2.97 [0.61, 14.41]	
Mathieson 2017	4	108	0	101	2.5%	8.42 [0.46, 154.48]	
Subtotal (95% CI)		218		210	11.2%	3.77 [0.94, 15.08]	
Total events	10		2				
Heterogeneity: Tau2:	= 0.00; Chi	z = 0.39	9, df = 1 (1)	P = 0.53	3); I² = 0%		
Test for overall effect	: Z= 1.87 (P = 0.0	6)				
2.1.2 Peripheral neu	ropathic p	ain					
Arezzo 2008	12	82	1	85	5.3%	12.44 [1.65, 93.52]	
Freynhagen 2005	35	273	2	65	11.0%	4.17 [1.03, 16.88]	-
Guan 2011	15	206	2	102	10.1%	3.71 [0.87, 15.93]	
Holbech 2015	10	18	4	19	23.1%	2.64 [1.01, 6.92]	-
Huffman 2015	5	101	1	102	4.7%	5.05 [0.60, 42.46]	
Rauck 2013	5	66	1	120	4.8%	9.09 [1.08, 76.19]	-
Richter 2005	9	161	0	85	2.7%	10.09 [0.59, 171.22]	
Satoh 2011	20	179	3	135	15.1%	5.03 [1.53, 16.57]	
Simpson 2014	2	183	1	194	3.8%	2.12 [0.19, 23.18]	
Stacey 2008	12	179	0	90	2.7%	12.64 [0.76, 211.08]	+
Tolle 2008	19	299	0	96	2.7%	12.61 [0.77, 206.90]	+
van Seventer 2006	19	275	0	93	2.7%	13.28 [0.81, 217.85]	+ +
Subtotal (95% CI)		2022		1186	88.8%	4.69 [2.87, 7.68]	•
Total events	163		15				
Heterogeneity: Tau ² :			•	(P = 0.9)	$90); I^2 = 0$	%	
Test for overall effect	: Z= 6.16 ((P < 0.0	0001)				
Total (95% CI)		2240		1396	100.0%	4.58 [2.88, 7.28]	•
Total events	173		17				
Heterogeneity: Tau2:	= 0.00; Chi	² = 5.99	9, df = 13	(P = 0.5)	95); l² = 0°	%	0.01 0.1 1 10 100
Test for overall effect	: Z= 6.43 (P < 0.0	0001)				0.01 0.1 1 10 100 Favours pregabalin Favours placebo
Test for subgroup dit	ferences:	Chi ^z = 0	0.09, df=	1 (P = 1)	0.77), $I^2 =$	0%	i avouis pregaballii i avouis piacebo

Figure S3: Effect of pregabalin on the risk of somnolence in patients with neuropathic pain

	Pregat	oalin	Place	bo		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	
2.5.1 Central neuropath	hic pain							
Cardenas 2013	37	112	14	108	11.2%	2.55 [1.46, 4.44]		
Kim 2011	24	110	5	109	4.0%	4.76 [1.88, 12.01]		
Mathieson 2017	9	108	4	101	2.6%	2.10 [0.67, 6.62]	- -	
Siddall 2006	29	70	6	67	5.2%	4.63 [2.05, 10.43]		
Subtotal (95% CI)		400		385	23.1%	3.18 [2.16, 4.68]	-	
Total events	99		29					
Heterogeneity: Tau² = 0	•			= 0.44);	$I^2 = 0\%$			
Test for overall effect: Z	= 5.87 (P	< 0.000	001)					
2.5.2 Peripheral neuro	nathic pai	in						
Arezzo 2008	11	 82	5	85	3.4%	2.28 [0.83, 6.28]		
Dworkin 2003	22	89	6	84	4.8%	3.46 [1.48, 8.11]		
Freynhagen 2005	32	273	0	65	0.4%	15.66 [0.97, 252.40]		
Guan 2011	16	206	3	102	2.4%	2.64 [0.79, 8.86]		
Huffman 2015	12	101	4	102	2.9%	3.03 [1.01, 9.08]		
Krcevski Škvarč 2010	9	14	4	15	4.0%	2.41 [0.96, 6.08]		
Lesser 2004	44	240	4	97	3.5%	4.45 [1.64, 12.04]		
Liu 2015	6	111	5	109	2.6%	1.18 [0.37, 3.75]		_
Rauck 2013	9	66	5	120	3.1%	3.27 [1.14, 9.36]		•
Richter 2005	22	161	3	85	2.5%	3.87 [1.19, 12.57]		
Rosenstock 2004	15	76	2	70	1.7%	6.91 [1.64, 29.13]		
Sabatowski 2004	30	157	6	81	5.0%	2.58 [1.12, 5.94]		
Satoh 2011	46	179	11	135	9.0%	3.15 [1.70, 5.86]		
Simpson 2010	35	151	13	151	9.8%	2.69 [1.48, 4.88]	-	
Simpson 2014	13	183	4	194	2.8%	3.45 [1.14, 10.37]		
Stacey 2008	27	179	2	90	1.7%	6.79 [1.65, 27.91]		\longrightarrow
Tolle 2008	17	299	1	96	0.9%	5.46 [0.74, 40.48]		
van Seventer 2006	42	275	4	93	3.5%	3.55 [1.31, 9.64]		•
van Seventer 2010	20	127	8	127	5.7%	2.50 [1.14, 5.47]		
Vranken 2008	9	20	9	20	7.4%	1.00 [0.50, 1.98]		
Subtotal (95% CI)		2989		1921	76.9%	2.74 [2.22, 3.40]	•	-
Total events	437		99					
Heterogeneity: Tau² = 0			•	P = 0.4	$(4); I^2 = 1\%$	6		
Test for overall effect: Z	= 9.25 (P	< 0.000	001)					
Total (95% CI)		3389		2306	100.0%	2.84 [2.36, 3.42]	•	•
Total events	536		128					
Heterogeneity: Tau² = 0	.00; Chi ² :	= 22.21	df= 23	P = 0.5	i1); I² = 0%	5	.1 0.2 0.5 1 2	5 10
Test for overall effect: Z							.1 0.2 0.5 1 2 Favours pregabalin Favours pla	
Test for subgroup differ	ences: Cl	hi = 0.4	3, df = 1	(P = 0.9)	51), I² = 09	%	r avours pregaballit i avours pla	0000

Figure S4: Effect of pregabalin on the risk of dizziness in patients with neuropathic pain

	Pregat		Place			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
2.6.1 Central neuropat	hic pain						
Cardenas 2013	20	112	6	108	3.7%	3.21 [1.34, 7.70]	
Kim 2011	31	110	8	109	4.3%	3.84 [1.85, 7.97]	
Mathieson 2017	70	108	19	101	5.8%	3.45 [2.25, 5.29]	
Siddall 2006	17	70	6	67	3.7%	2.71 [1.14, 6.46]	
Subtotal (95% CI)		400		385	17.5%	3.38 [2.46, 4.63]	-
Total events	138		39				
Heterogeneity: Tau² = 0				= 0.94);	I ² = 0%		
Test for overall effect: Z	= 7.52 (P	< 0.000	001)				
2.6.2 Peripheral neuro	pathic pai	in					
Arezzo 2008	27	82	5	85	3.6%	5.60 [2.27, 13.83]	
Dworkin 2003	25	89	10	84	4.6%	2.36 [1.21, 4.61]	
Freynhagen 2005	65	273	3	65	2.8%	5.16 [1.67, 15.90]	
Guan 2011	103	206	41	102	6.5%	1.24 [0.95, 1.63]	
Holbech 2015	11	18	3	19	2.9%	3.87 [1.29, 11.65]	
Huffman 2015	11	101	6	102	3.4%	1.85 [0.71, 4.82]	
Krcevski Škvarč 2010	9	14	4	15	3.5%	2.41 [0.96, 6.08]	-
Lesser 2004	60	240	5	97	3.7%	4.85 [2.01, 11.71]	
Liu 2015	27	111	4	109	3.2%	6.63 [2.40, 18.31]	
Rauck 2013	9	66	7	120	3.4%	2.34 [0.91, 5.99]	 •
Richter 2005	45	161	2	85	2.1%	11.88 [2.95, 47.78]	
Rosenstock 2004	27	76	8	70	4.4%	3.11 [1.51, 6.38]	
Sabatowski 2004	31	157	12	81	4.9%	1.33 [0.72, 2.45]	- •
Satoh 2011	43	179	9	135	4.5%	3.60 [1.82, 7.13]	
Simpson 2010	29	151	16	151	5.1%	1.81 [1.03, 3.20]	-
Simpson 2014	25	183	10	194	4.4%	2.65 [1.31, 5.36]	
Stacey 2008	49	179	6	90	4.0%	4.11 [1.83, 9.22]	
Tolle 2008	26	299	2	96	2.1%	4.17 [1.01, 17.26]	
van Seventer 2006	79	275	9	93	4.7%	2.97 [1.55, 5.68]	
van Seventer 2010	55	127	12	127	5.1%	4.58 [2.58, 8.14]	
Vranken 2008	7	20	6	20	3.6%	1.17 [0.48, 2.86]	
Subtotal (95% CI)		3007		1940	82.5%	2.89 [2.17, 3.85]	_
Total events	763		180			070	
Heterogeneity: Tau ² = 0				(P < U.U	0001); I*:	= 67%	
Test for overall effect: Z	= 1.21 (P	< U.UUL	JUT)				
Total (95% CI)		3407		2325	100.0%	2.94 [2.30, 3.74]	•
Total events	901		219				
Heterogeneity: Tau ² = 0				(P < 0.0	1001); I²=	63%	0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z				<i>(</i> D	400 17 0	~	Favours pregabalin Favours placebo
Test for subgroup differ	ences: Cl	nı== 0.5	U, df = 1	(P=0.4	48), $I^2 = 0^\circ$	%	-

Figure S5: Effect of pregabalin on the risk of peripheral edema in patients with neuropathic pain




Figure S6: Effect of pregabalin on the risk of fatigue including asthenia in patients with neuropathic pain

	Pregab	alin	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events		Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Arezzo 2008	8	82	1	82	2.4%	8.00 [1.02, 62.53]	
Cardenas 2013	8	112	1	108	2.4%	7.71 [0.98, 60.65]	
Freynhagen 2005	21	273	0	65	1.3%	10.36 [0.64, 168.79]	
Guan 2011	23	206	7	102	11.9%	1.63 [0.72, 3.66]	-
Holbech 2015	7	18	3	19	6.5%	2.46 [0.75, 8.09]	
Huffman 2015	11	101	3	102	6.0%	3.70 [1.06, 12.88]	
Krcevski Škvarč 2010	8	14	8	15	15.9%	1.07 [0.56, 2.06]	
Lesser 2004	13	240	3	97	6.1%	1.75 [0.51, 6.01]	
Liu 2015	5	111	1	109	2.2%	4.91 [0.58, 41.35]	
Rauck 2013	4	66	3	120	4.5%	2.42 [0.56, 10.51]	
Richter 2005	13	161	3	85	6.1%	2.29 [0.67, 7.81]	
Rosenstock 2004	3	76	2	70	3.2%	1.38 [0.24, 8.03]	
Sabatowski 2004	7	157	4	81	6.4%	0.90 [0.27, 2.99]	
Stacey 2008	13	179	1	90	2.5%	6.54 [0.87, 49.18]	+
Tolle 2008	10	299	0	96	1.3%	6.79 [0.40, 114.81]	
van Seventer 2006	12	275	5	93	8.4%	0.81 [0.29, 2.24]	
van Seventer 2010	15	127	10	127	13.0%	1.50 [0.70, 3.21]	-
Total (95% CI)		2497		1461	100.0%	1.83 [1.32, 2.54]	
Total events	181		55				
Heterogeneity: Tau² = 0.	.06; Chi ² =	= 18.63	, df = 16 (P = 0.2	9); l² = 14	·%	0.2 0.5 1 2 5
Test for overall effect: Z	= 3.62 (P	= 0.000	03)				Favours pregabalin Favours placebo
	•		-				ravouis pregavaiiii ravouis piacevo

Figure S7: Effect of pregabalin on the risk of visual disturbances* in patients with neuropathic pain

	Pregab		Place			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
2.8.1 Central neuropath							
Cardenas 2013	7	112	0	108	2.9%	14.47 [0.84, 250.29]	
Mathieson 2017	4	108	1	101	4.9%	3.74 [0.43, 32.91]	
Siddall 2006	6	70	2	67	9.1%	2.87 [0.60, 13.73]	-
Subtotal (95% CI)		290		276	17.0%	4.05 [1.27, 12.91]	
Total events	17		3				
Heterogeneity: Tau ² = 0.	00; Chi²=	= 1.03, (df = 2 (P :	= 0.60);	$I^2 = 0\%$		
Test for overall effect: Z:	= 2.36 (P	= 0.02)					
2.8.2 Peripheral neurop	athic pai	in					
Dworkin 2003	10	89	1	84	5.6%	9.44 [1.23, 72.14]	
Holbech 2015	3	18	0	19	2.8%	7.37 [0.41, 133.37]	-
Huffman 2015	4	101	1	102	4.9%	4.04 [0.46, 35.52]	
Krcevski Škvarč 2010	2	14	3	15	8.4%	0.71 [0.14, 3.66]	
Lesser 2004	13	240	1	97	5.7%	5.25 [0.70, 39.62]	
Rauck 2013	3	66	5	120	11.2%	1.09 [0.27, 4.42]	•
Richter 2005	9	161	5	85	18.1%	0.95 [0.33, 2.75]	
Rosenstock 2004	4	76	1	70	5.0%	3.68 [0.42, 32.17]	-
Stacey 2008	8	179	0	90	2.9%	8.59 [0.50, 147.25]	
van Seventer 2006	19	275	1	93	5.8%	6.43 [0.87, 47.34]	
van Seventer 2010	8	127	3	127	12.7%	2.67 [0.72, 9.82]	
Subtotal (95% CI)		1346		902	83.0%	2.36 [1.32, 4.22]	
Total events	83		21				
Heterogeneity: Tau ² = 0.	16; Chi² =	= 11.95,	df= 10 ((P = 0.2)	9); I² = 18	3%	
Test for overall effect: Z	= 2.90 (P	= 0.004	1)				
Total (95% CI)		1636		1178	100.0%	2.50 [1.53, 4.09]	•
Total events	100		24				
Heterogeneity: Tau ² = 0.	06; Chi²=	= 13.90.	df = 13	(P = 0.3)	8); I² = 69	%	
Test for overall effect: Z:	•						0.1 0.2 0.5 1 2 5 10
Test for subgroup differ	•			P = 0	12) P = 01	96	Favours pregabalin Favours placebo

^{*}includes blurring of vision and amblyopia

Figure S8: Effect of pregabalin on the risk of ataxia in patients with neuropathic pain

	Pregab	alin	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Arezzo 2008	4	82	0	85	14.1%	9.33 [0.51, 170.52]	
Dworkin 2003	6	89	0	84	14.5%	12.28 [0.70, 214.63]	
Lesser 2004	15	240	2	97	56.1%	3.03 [0.71, 13.01]	
van Seventer 2006	20	275	0	93	15.2%	13.96 [0.85, 228.63]	•
Total (95% CI)		686		359	100.0%	5.49 [1.84, 16.36]	•
Total events	45		2				
Heterogeneity: Tau² =	0.00; Chi	$i^2 = 1.59$	9, df = 3 (F	o = 0.6	6); I² = 0%)	0.005 0.4 1 10 300
Test for overall effect:	Z = 3.06 ((P = 0.0)	02)				0.005 0.1 1 10 200 Favours pregabalin Favours placebo

Figure S9: Effect of pregabalin on the risk of non-peripheral edema in patients with neuropathic pain

Figure S10: Effect of pregabalin on the risk of vertigo in patients with neuropathic pain

	Pregab	alin	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Freynhagen 2005	24	273	1	65	22.5%	5.71 [0.79, 41.47]	-
Krcevski Škvarč 2010	7	14	5	15	51.8%	1.50 [0.62, 3.64]	-
Stacey 2008	6	179	0	90	12.7%	6.57 [0.37, 115.38]	-
Tolle 2008	13	299	0	96	13.1%	8.73 [0.52, 145.49]	-
Total (95% CI)		765		266	100.0%	3.08 [1.01, 9.40]	-
Total events	50		6				
Heterogeneity: Tau² = 0.	.42; Chi ^z :	4.31,	df = 3 (P :	= 0.23);	I ² = 30%		0.005 0.1 1 10 200
Test for overall effect: Z	= 1.97 (P	= 0.05)					Favours pregabalin Favours placebo

Figure S11: Effect of pregabalin on the risk of euphoria in patients with neuropathic pain

	Pregab	alin	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Cardenas 2013	3	112	0	108	15.9%	6.75 [0.35, 129.20]	-
Lesser 2004	9	240	0	97	17.2%	7.73 [0.45, 131.46]	-
Rosenstock 2004	4	76	0	70	16.4%	8.30 [0.45, 151.41]	
Simpson 2010	15	151	1	151	34.2%	15.00 [2.01, 112.13]	
Stacey 2008	4	179	0	90	16.3%	4.55 [0.25, 83.59]	•
Total (95% CI)		758		516	100.0%	8.80 [2.72, 28.54]	
Total events	35		1				
Heterogeneity: Tau² =	0.00; Chi	z = 0.51	I, df = 4 (I)	P = 0.9	7); $I^2 = 0\%$		0.005 0.1 1 10 200
Test for overall effect:	Z=3.63 (P = 0.0	003)				0.005 0.1 1 10 200 Favours pregabalin Favours placebo

Figure S12: Effect of pregabalin on the risk of dry mouth in patients with neuropathic pain

Pregabalin Placebo Risk Ratio Risk Ratio

	Pregat	oalin	Place	bo		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	
2.4.1 Central neuropat	hic pain							
Cardenas 2013	9	112	3	108	6.8%	2.89 [0.80, 10.40]	+	
Siddall 2006	11	70	2	67	5.3%	5.26 [1.21, 22.87]		
Subtotal (95% CI)		182		175	12.1%	3.75 [1.43, 9.83]		
Total events	20		5					
Heterogeneity: Tau² = 0	1.00; Chi ² :	= 0.37, (df=1 (P:	= 0.55);	$I^2 = 0\%$			
Test for overall effect: Z	= 2.68 (P	= 0.007	7)					
2.4.2 Peripheral neuro	pathic pa	in						
Arezzo 2008	4	82	1	85	2.6%	4.15 [0.47, 36.32]		
Dworkin 2003	10	89	2	84	5.2%	4.72 [1.07, 20.91]		
Freynhagen 2005	12	273	3	65	7.2%	0.95 [0.28, 3.28]		
Holbech 2015	7	18	3	19	7.6%	2.46 [0.75, 8.09]		
Huffman 2015	5	101	1	102	2.7%	5.05 [0.60, 42.46]	-	
Krcevski Škvarč 2010	11	14	8	15	21.0%	1.47 [0.85, 2.55]	+-	
Lesser 2004	8	240	0	97	1.6%	6.91 [0.40, 118.61]	-	\longrightarrow
Liu 2015	6	111	3	109	6.1%	1.96 [0.50, 7.66]	- •	
Rauck 2013	1	65	4	120	2.6%	0.46 [0.05, 4.04]	· · · · · · · · · · · · · · · · · · ·	
Richter 2005	7	161	3	109	6.3%	1.58 [0.42, 5.98]	- •	
Sabatowski 2004	14	157	3	81	7.3%	2.41 [0.71, 8.14]	 •	
Simpson 2010	14	151	1	151	3.0%	14.00 [1.86, 105.13]		\longrightarrow
Tolle 2008	15	299	0	96	1.6%	10.02 [0.61, 165.96]	-	
van Seventer 2006	20	275	0	93	1.6%	13.96 [0.85, 228.63]	+	\longrightarrow
van Seventer 2010	14	127	6	127	11.2%	2.33 [0.93, 5.88]	+	
Subtotal (95% CI)		2163		1353	87.9%	2.28 [1.52, 3.41]	-	
Total events	148		38					
Heterogeneity: Tau² = 0				(P = 0.2)	$(3); I^2 = 20$	1%		
Test for overall effect: Z	= 3.99 (P	< 0.000	01)					
Total (95% CI)		2345		1528	100.0%	2.39 [1.66, 3.44]	•	
Total events	168		43					
Heterogeneity: Tau² = 0				(P = 0.2)	$(7); I^2 = 16$	i%	0.1 0.2 0.5 1 2	5 10
Test for overall effect: Z	•						Favours pregabalin Favours placeb	
Test for subgroup differ	rences: Cl	hi = 0.8	37, df = 1	(P = 0.3)	35), I² = 0°	%	. 1.1310 progadam arouro piacon	_

Figure S13: Effect of pregabalin on the risk of discontinuation due to adverse events




Figure S14: Effect of pregabalin on the risk of serious adverse events in patients with neuropathic pain




Figure S15: Effect of pregabalin on the sleep disturbance in patients with neuropathic pain

	Pred	jabali	n	PI	acebo			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean			Mean	SD			IV, Random, 95% CI	IV, Random, 95% CI
4.1.1 Central neuropa	athic pair	n							
Cardenas 2013	-2.1	2.15	112	-1.02	2.04	108	14.3%	-0.51 [-0.78, -0.24]	
Siddall 2006	-1.43	2.55	70	-0.27	2.65	67	10.2%	-0.44 [-0.78, -0.10]	
Subtotal (95% CI)			182			175	24.5%	-0.49 [-0.70, -0.28]	-
Heterogeneity: Tau² =	0.00; Ch	ii = 0.	10, df=	= 1 (P =	0.75);	$I^2 = 0\%$	ı		
Test for overall effect:	Z = 4.53	(P < 0	.00001)					
4.1.2 Peripheral neur	opathic p	pain							
Liu 2015	-1.24	1.58	111	-0.7	1.57	109	14.5%	-0.34 [-0.61, -0.08]	
Simpson 2010	-1.04	1.99	151	-0.68	2.14	151	17.9%	-0.17 [-0.40, 0.05]	
Tolle 2008	-2.4	1.99	70	-1.7	2.14	70	10.4%	-0.34 [-0.67, -0.00]	
van Seventer 2006	-1.96	2.06	275	-0.7	2.03	93	16.7%	-0.61 [-0.85, -0.37]	
van Seventer 2010	-1.37	2.4	127	-0.67	2.7	127	16.0%	-0.27 [-0.52, -0.03]	
Subtotal (95% CI)			734			550	75.5%	-0.35 [-0.50, -0.19]	•
Heterogeneity: Tau² =			•		0.12);	$I^2 = 45^\circ$	%		
Test for overall effect:	Z = 4.34	(P < 0	.0001)						
Total (95% CI)			916			725	100.0%	-0.38 [-0.50, -0.26]	•
Heterogeneity: Tau² =	0.01: Ch	i² = 8		6 (P =	n 10\·				
Test for overall effect:			•		0.13),	1 - 32	,0		-1 -0.5 0 0.5 1
Test for subgroup diff		•		•	5 = U 3	n) iz –	2 N%		Favours pregabalin Favours placebo
restroi subdroub aiii	61611668.	VIII -	- 1.03,	G1 - 1 (1	- 0.3	U). I —	0.0 /0		

Figure S16: Effect of pregabalin on HADS-anxiety scores in patients with neuropathic pain

	Preg	jabali	n	Pl	acebo			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
5.3.1 Central neuropa	athic pair	1							
Cardenas 2013	-1.5	3.4	100	-0.82	3.28	99	21.7%	-0.20 [-0.48, 0.08]	
Kim 2011	-1.9	3.4	110	-0.8	3.28	109	22.9%	-0.33 [-0.59, -0.06]	
Subtotal (95% CI)			210			208	44.5%	-0.27 [-0.46, -0.08]	♦
Heterogeneity: Tau² =	0.00; Ch	$i^2 = 0$.	41, df=	1 (P=	0.52);	$l^2 = 0\%$)		
Test for overall effect:	Z = 2.73	(P = 0	.006)						
5.3.2 Peripheral neur	opathic	pain							
Simpson 2014	-1.09	6.36	183	-1.39	6.93	192	30.7%	0.04 [-0.16, 0.25]	<u>+</u>
van Seventer 2010	-1.4	6.36	124	-0.9	6.93	124	24.8%	-0.07 [-0.32, 0.17]	-
Subtotal (95% CI)			307			316	55.5%	-0.00 [-0.16, 0.15]	♦
Heterogeneity: Tau ² =	0.00; Ch	$\mathbf{i}^{\mathbf{z}} = 0.$	54, df=	1 (P=	0.46);	$I^2 = 0\%$)		
Test for overall effect:	Z = 0.03	(P = 0	1.97)						
Total (95% CI)			517			524	100.0%	-0.12 [-0.29, 0.04]	•
Heterogeneity: Tau ² =	0.01; Ch	$i^2 = 5$.	32, df=	3 (P=	0.15);	$l^2 = 44^{\circ}$	%	-	_
Test for overall effect:			•	•					-4 -2 U 2 4
Test for subgroup diff	erences:	Chi²÷	= 4.38,	df = 1 (F	o.0 = °	4), ²=	77.2%		Favours pregabalin Favours placebo

Figure S17: Effect of pregabalin on HADS-depression scores in patients with neuropathic pain

	Pregabalin			Placebo				Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
5.4.1 Central neuropathic pain									
Cardenas 2013	-1.09	3.4	100	-0.1	3.38	99	22.6%	-0.29 [-0.57, -0.01]	
Kim 2011	-1.2	3.4	110	-1.1	3.38	109	23.7%	-0.03 [-0.29, 0.24]	, †
Subtotal (95% CI)			210			208	46.3%	-0.16 [-0.41, 0.10]	•
Heterogeneity: Tau² = 0.01; Chi² = 1.77, df = 1 (P = 0.18); l² = 44%									
Test for overall effect:	Z=1.20	(P = 0	0.23)						
5.4.2 Peripheral neuropathic pain									
Simpson 2014	0.12	6.16	183	-0.9	6.36	192	28.8%	0.16 [-0.04, 0.37]	-
van Seventer 2010	-1.2	6.16	124	-0.3	6.36	124	24.9%	-0.14 [-0.39, 0.11]	-
Subtotal (95% CI)			307			316	53.7%	0.02 [-0.28, 0.32]	•
Heterogeneity: Tau² = 0.03; Chi² = 3.48, df = 1 (P = 0.06); l² = 71%									
Test for overall effect:	Z = 0.12	(P = 0).90)						
Total (95% CI)			517			524	100.0%	-0.06 [-0.26, 0.13]	+
Heterogeneity: $Tau^2 = 0.02$; $Chi^2 = 7.59$, $df = 3$ (P = 0.06); $I^2 = 60\%$									
Test for overall effect: Z = 0.61 (P = 0.54)								Favours pregabalin Favours placebo	
Test for subgroup differences: Chi ² = 0.76, df = 1 (P = 0.38), l ² = 0%									